Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T89 for chronic stable angina pectoris
ACTRN12609000044224Phase 2Terminated
- Sponsor
- CNS Pharmaceuticals
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in angina pectoris comparing T89 with Placebo (2 arms). Primary endpoint: Change in total exercise duration at trough drug levels. Started Jun 2008; status: terminated.
02
Drugs
Compound Danshen
03
Conditions
angina pectoris
Beyond the preview
Go deeper on ACTRN12609000044224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000044224.